Coherus Oncology, Inc. (FRA:8C5)

Germany · Delayed Price · Currency is EUR

1.440

+0.075 (5.46%)

At close: Feb 20, 2026

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Developing and Commercializing Biosimilar Products	266.96M	257.24M	211.04M	326.55M	475.82M
Developing and Commercializing Biosimilar Products Growth	3.78%	21.89%	-35.37%	-31.37%	33.63%
Total	266.96M	257.24M	211.04M	326.55M	475.82M
Total Growth	3.78%	21.89%	-35.37%	-31.37%	33.63%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States of America	266.96M	257.24M	211.04M	326.55M	475.82M
United States of America Growth	3.78%	21.89%	-35.37%	-31.37%	33.63%
Total	266.96M	257.24M	211.04M	326.55M	475.82M
Total Growth	3.78%	21.89%	-35.37%	-31.37%	33.63%

Source: S&P Global Market Intelligence.